MARKETSnap
  • Market Snapshots
    • Gainers & Losers
    • Most Active & More
    • 52-Week High/Low
    • Dividends
    • P/E Ratios
      • Large Caps
      • Absolute
      • Total Market PE
    • Stocks Performance
      • Large Caps
      • Absolute
    • Industries Performance
      • Industry
      • Sector
  • Analyze Stock
    • Analyze a stockAnalyze 2385.T →
    • FindStock Picks / Stock Screener
    • Value · 2385.TIntrinsic Value Calculator
    • Invest · 2385.TInvestment Case
    • Hold · 2385.T5-Year Outlook
  • Learn
  • Calendar
  • Investment Compounding
    Calculator
  • Investing Philosophy
  • More
    • Charts
    • Commodities
    • Currencies
    • Economic Indicators
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
2385

2385.T

Soiken Holdings Inc.

$206
-1
 (-0.48%)
Exchange:  JPX
Market Cap:  5.389B
Shares Outstanding:  26.158M
Delayed data
Overview
Earnings
Financials
Valuation
Chart

About The Company

Sector:  HealthcareView sector performance
Industry:  BiotechnologyView industry performance
   
CEO:  Kentaro Ishigami
Full Time Employees:  45
Address: 
Senri Life Science Center
Toyonaka
OS
560-0082
JP
Website:  https://www.soiken.com
Founded in 1994 and headquartered in Toyonaka, Japan, Soiken Holdings Inc. primarily focuses on the advancement of biomarkers. The company’s operations span a diverse range of health and wellness sectors. It is actively involved in the creation and commercialization of cosmetics and nutritional supplements, alongside the licensing and continued development of biomarker technologies. Soiken also conducts market research and post-market surveillance specifically for dietary supplements. A key area of its work includes the research, development, and sale of functional materials like lactoferrin, as well as pharmaceuticals derived from ascochlorin. Furthermore, Soiken applies its biomarker expertise to perform clinical evaluations for food products. The company extends its services to provide vital support for physician-initiated pharmaceutical clinical research, comprehensive health screenings, and personalized health guidance. It also partners with health insurance societies to offer contracted health guidance, facilitate specialized health check-ups for dependents of the insured, and implement programs designed for diabetes prevention.

Click to read more…

Revenue Segmentation

🔒 You are currently logged out

Login

It’s free

Industry Peers

TICKERCOMPANYMKT CAPP/EFWD P/EROIC
232385.T logo2385.TSoiken Holdings Inc.5.4B26.1—4.2%
SRSRRK logoSRRKScholar Rock Holding Corporation5.4B——-88.8%
COCOGT logoCOGTCogent Biosciences, Inc.5.3B——-50.1%
MAMANE logoMANEVeradermics, Incorporated5.5B——-12.6%
CGCGON logoCGONCG Oncology Inc.5.7B——-24.3%
PTPTCT logoPTCTPTC Therapeutics, Inc.5.7B—1305.7%

EPS

Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.

Log in to continue

Log in for the full EPS chart and links to analyst estimates.

Login — it's free
View full analyst estimates

Earnings Call

No earnings call materials on file for this symbol yet.

Log in to continue

Log in to read the full transcript and AI-generated earnings summaries.

Login — it's free
Income Statement
Balance Sheet
Cash Flow Statement
Analyst Estimates

Income Statement

Year202320242025
Revenue5,158,4584,848,5343,871,358
Gross Profit2,482,3732,410,4751,866,390
EBITDA-583,206-201,925287,515
Operating Income-610,007-137,540274,105
Net Income-662,204-210,696212,289

Log in to continue

Log in to see the income statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Balance Sheet

Year202320242025
Total Assets6,957,6906,812,8996,851,930
Total Liabilities708,579775,156742,476
Total Stockholders Equity6,232,8716,022,1756,109,454
Total Debt000
Cash and Cash Equivalents4,790,0244,958,3515,352,796

Log in to continue

Log in to see the balance sheet and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Cash Flow Statement

Year202320242025
Operating Cash Flow-880,822557,955415,149
Capital Expenditure-14,599-36,763.999-37,945
Free Cash Flow-895,421521,191377,204
Net Income-662,000-210,696212,289
Net Change in Cash-1,155,830168,327394,445

Log in to continue

Log in to see the cash flow statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Analyst Estimates

Fiscal Year2025Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (Low)8,970,000Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (High)8,970,000Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (Avg)8,970,000Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (Low)814,217.919Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (High)814,217.919Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (Avg)814,217.919Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (Low)659,997.518Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (High)659,997.518Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (Avg)659,997.518Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (Low)3,927,461.507Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (High)3,927,461.507Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (Avg)3,927,461.507Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (Avg)25.230Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (High)25.230Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (Low)25.230Research AccessResearch AccessResearch AccessResearch Access
Number of Analysts (Estimated Revenue)1Research AccessResearch AccessResearch AccessResearch Access
Number of Analysts (Estimated EPS)1Research AccessResearch AccessResearch AccessResearch Access

Log in to continue

Log in and subscribe to Full Access to see up to 5 years of analyst estimates.

Login — it's free

(* All numbers are in thousands)

Current Key Metrics

?Revenue
 (TTM)
: 
  ?P/S
 (TTM)
: 
1.43
?Net Income
 (TTM)
: 
  ?P/E
 (TTM)
: 
26.11
?Enterprise Value
 (TTM)
: 
192.742M  ?EV/FCF
 (TTM)
: 
0
?Dividend Yield
 (TTM)
: 
4.72%  ?Payout Ratio
 (TTM)
: 
0%
?ROE
 (TTM)
: 
3.5%  ?ROIC
 (TTM)
: 
4.16%
?Net Debt
 (TTM)
: 
  ?Debt/Equity
 (TTM)
: 
0
?P/B
 (TTM)
: 
0.91  ?Current Ratio
 (TTM)
: 
8.98

Log in to continue

Log in to see all key valuation metrics and ratios for this symbol.

Login — it's free

Forward P/E Ratios

?

Forward P/E (Avg EPS estimate) — log in with Research Access for high/low estimates and the interactive table.

Forward P/E 1YResearch AccessResearch AccessResearch AccessResearch Access
N/AResearch AccessResearch AccessResearch AccessResearch Access

Log in to continue

Log in with Full Access for forward P/E high/low estimates and the full multi-year table.

Login — it's free

SWOT Analysis

🔒 You are currently logged out

Login

It's free

At what price to buy it? -
Intrinsic Value Calculator

Based on current fundamentals and analyst forecasts, MarketSnap estimates 2385.T intrinsic value between $1.10 – $1.17 per share. This depends on revenue growth, margins, and discount rate.

This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.


Calculate T Intrinsic Value

Common questions about 2385.T valuation

Is Soiken Holdings Inc. (2385.T) overvalued or undervalued right now?

MarketSnap estimates intrinsic value for Soiken Holdings Inc. (2385.T) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.

Is 2385.T a buy, hold, or sell for long-term investors?

MarketSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether 2385.T trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.

What is 2385.T’s P/E ratio?

You can see 2385.T’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.

How is intrinsic value calculated for 2385.T?

MarketSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MarketSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.

Is 2385.T a good long-term investment?

Whether 2385.T fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MarketSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.

Research tools for Soiken Holdings Inc.

  • Soiken Holdings Inc. intrinsic value calculatorEstimate what the business is worth
  • Soiken Holdings Inc. 5-year outlookWhat has to go right, and what could go wrong
2385.T

1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.

Daily snapshot

-0.48
MarketSnap

Trading Metrics:

Open: 209   Previous Close: 207
Day Low: 201   Day High: 210
Year Low: 182   Year High: 325
Price Avg 50: 218.92   Price Avg 200: 235.52
Volume: 110000   Average Volume: 214260

Log in to continue

Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.

Login — it's free
See in Nexus

Relevant news

DISCLAIMER: The stock market data provided on this website is for informational purposes only and is not intended for trading purposes. While we strive to provide accurate and timely information, we cannot guarantee that the information is accurate at the moment it is received or that it will continue to be accurate in the future. We are not responsible for any actions taken based on the information provided on this website. Always consult with a licensed financial professional before making any investment decisions.
Terms of Service

Copyright © 2025 MarketSnap. All rights reserved.

Contact Us

Privacy Policy

Cookie Policy

Terms of Service

Hover Image
MARKETSnap

Market

🇺🇸 United States

Language

    • Gainers & Losers
    • Most Active & More
    • 52-Week High/Low
    • Dividends
      • Large Caps
      • Absolute
      • Total Market PE
      • Large Caps
      • Absolute
      • Industry
      • Sector
    • Analyze a stockAnalyze 2385.T →
    • FindStock Picks / Stock Screener
    • Value · 2385.TIntrinsic Value Calculator
    • Invest · 2385.TInvestment Case
    • Hold · 2385.T5-Year Outlook
  • Learn
  • Calendar
  • Investment Compounding Calculator
    • Charts
    • Commodities
    • Currencies
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
  • Investing Philosophy
  • Nexus
    • Recent Activity
      • Overview
      • My Valuations
      • My Investment Journal
      • Watchlists & Portfolio
    • Settings
    • Public profile ↗
  • Log in

Media

Watch Listen Read